Drugs / anti-Her-2 cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00924287 | Nov 2008 → Dec 2010 | metastatic malignant neoplasm | National Cancer Institute (NCI) | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-Her-2 cells | “The modified cells (anti-Her-2 cells) are grown in the laboratory and then given back to the patient to try to decrease the size of the tumors.” NCT00924287 ↗ |
| Modality | Cell therapy | “The cells are genetically modified using the anti-Her-2 gene and a type of virus.” NCT00924287 ↗ |
| Route | Intravenous | “The cells are given as an infusion through a vein.” NCT00924287 ↗ |